Registry for Online Adaptive Radiotherapy in Pelvic and Thoracic Tumors
Official title: Pelvic and Thoracic Cancer Treated With Online Adapted Radiotherapy: A Prospective Registry-based Phase-II Trial
Run by University Medical Center Goettingen · NCT06185062 · Data updated 2026-11-12
This study is testing if a new type of radiotherapy that adapts to patients' changing needs can reduce side effects and improve outcomes for people with pelvic or thoracic tumors compared to standard treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 846 (estimated) |
| Sponsor | University Medical Center Goettingen Academic / other |
| Locations | 1 site (Göttingen) |
| Status | Recruiting |
| Started | January 1, 2024 |
| Main results expected | September 2029 |
| Study ends | April 2030 |
| Registry record updated | February 8, 2024 |
| Trial ID | NCT06185062 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with pelvic or thoracic tumors that require radiotherapy.
✕Probably not a fit
Patients who have previously received radiotherapy at the affected site will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational registry-based trial aims to include patients with pelvic or thoracic tumors who require radiotherapy. It will compare the effectiveness of online Adaptive Radiotherapy (oART) against Image Guided Radiotherapy (IGRT) in reducing acute radiotherapy-related toxicity and improving clinical outcomes. The study will assess both clinical endpoints, such as tumor control and quality of life, and technical endpoints related to treatment precision. By utilizing daily imaging and artificial intelligence, the trial seeks to adapt treatment plans to the patient's current anatomy, potentially minimizing side effects.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the rate of acute toxicity associated with radiotherapy for patients with pelvic and thoracic tumors.
How similar studies have gone: While online Adaptive Radiotherapy is already in clinical use, this specific comparative analysis against IGRT is novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
INCLUSION CRITERIA * Patients with pelvic or thoracic tumors with an indication for radiotherapy * Patient information and declaration of consent * Patients age ≥ 18 years EXCLUSION CRITERIA * Prior radiotherapy in affected site
Where it's running
-
University Medical Center, Departement of Radiation Oncology
Göttingen, Germany Recruiting
Study contacts
- Study coordinator: Laura Anna Fischer
- Email: laura-anna.fischer@med.uni-goettingen.de
- Phone: +49 551 3964501
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Daily adjustment of radiation dose in MRI-guided SBRT for abdominal and pelvic tumors
This trial tests whether adjusting the radiation dose in real-time during MRI-guided SBRT improves targeting for abdominal or pelvic tumors.
-
Using 3D models to improve surgery for children's pelvic and retroperitoneal tumors
This study is testing if using 3D models of tumors can help doctors plan surgeries better for children with pelvic and retroperitoneal tumors compared to regular 2D images.
-
Using SBRT for reirradiation of ultra-central thoracic tumors
This study is testing if a special type of radiation therapy called SBRT can safely treat patients with tough-to-reach lung tumors that have come back after previous radiation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.